研究テーマ

これからの薬剤師には、高い生命倫理観と薬学専門知識に基づく薬物療法の実践に積極的に関与し、臨床現場の問題点を解決する研究的思考能力が求められています。臨床薬学教育研究センターでは、最先端の教育手法や評価方法の研究や常に臨床との繋がりを意識した臨床研究を通して、質の高い薬剤師教育を提供することを目指しています。
 

キーワード

 

配属学生

大学院生 2名
学部学生 6年次生:18名、5年次生:16名、4年次生:14名

所属教員

研究内容

(1)服用メディアによる薬物の消化管吸収変動機構の解析

医薬品は,水またはお湯での服用が推奨されていますが、日本では緑茶やジュースをはじめとする様々な飲みものがペットボトル飲料や缶飲料として容易に手に入るため、これらの飲料で医薬品を服用する機会も多いと予想されます。特に高齢者では緑茶が、小児では薬の苦みをなくすためにフルーツジュースなどが使用されているケースが多いと思われます.これまでに、認知症治療薬やアレルギー治療薬の一部を緑茶や紅茶と混合すると消化管吸収性が顕著に低下する可能性があることを明らかにしました。さらに、アレルギー治療薬フェキソフェナジン塩酸塩は、茶葉飲料以外にリンゴジュースやオレンジジュース等のフルーツジュースとの混合により消化管吸収性が低下する可能性を示しました。しかし,これらの現象が生じる詳細なメカニズムについては明らかではありません。現在、より安全な薬物療法を行うため、各飲料中の物質と医薬品間に生じる相互作用について詳細な検討を進めています。このような薬物-服用メディア相互作用の組み合わせは無数にあることから、様々なケースに触れることの多い病院や薬局からの情報に基づいた研究を展開することにより、相互作用回避のための注意喚起、啓発活動に繋げていければと考えています。

(2)循環器疾患薬物療法ならびに癌化学療法の有効性と安全性に対するバイオマーカーの探索と臨床評価

薬物の効果や副作用は、薬物血中濃度との関連性が強く示唆されており、それらの発現予測を行う上で薬物体内動態の規定因子の解析が必須となります。また、薬物体内動態は主に代謝酵素やトランスポーターによって規定され、それらをコードする遺伝子には多数の遺伝的多型が存在します。これまでに私たちは、治療薬物モニタリングを実施された患者やがん化学療法を施行された患者を対象に遺伝子多型解析を行い、薬物の体内動態や薬効・副作用の発現が種々の薬物代謝酵素や薬物トランスポーターの遺伝子多型と関連することを明らかにしてきました。一方で、がん患者臨床検体を用いて定量的プロテオーム解析を行い、同定されたタンパク質をがん治療のための創薬ターゲットあるいは診断バイオマーカーの候補とし、その発現変動の要因解明を行っています。さらに、がん化学療法の薬効・副作用の個体差を規定する因子として生体内金属元素(バイオメタル)に着目して、シスプラチンなどの白金製剤である抗がん剤投与後のバイオメタルの生体内挙動についても解析を進めています。
多様なバイオマーカーを探索・評価し、より効果的で安全な薬物療法の実施が可能となるように研究成果を臨床に還元することを目指しています。

(3)医薬品情報学的アプローチによる薬物療法のリスク最小化研究

薬物療法において、時に望ましくない反応が起きることがあります。これを可能な限り回避するためには、安全性の高い医薬品の開発に加え、有効性・安全性を高めた使い方をする必要があります。そのためには、市販後の日常診療から得られる様々な情報をデータベース化し、解析することでリスク情報を抽出し、安全対策に役立てることが有用と考えています。そのために、以下の手順に従い解析研究ならびに臨床における実証研究を行います。

①大規模なデータベースを用いて、有害事象のシグナルを抽出する。
②有害事象の発現要因ならびに医薬品との関連性を調査し、検証する。
③検証の結果から、医薬品との関連性が明らかとされたリスクに関してリスク最小化のための対策を立案し、臨床にフィードバックする。
④臨床における対策の有用性を評価し、改善点があれば改善策を検討する。
⑤実践者が患者である場合は、最適な情報提供方法を研究する。
⑥患者への情報提供並びに指導により、適切な行動がとれているかを検証する。
⑦総合評価

上記と並行して、超高齢社会が抱える問題に対して、実際にコミュニティに出て問題を抽出し、地域の様々な職種と協力し合って解決策を模索する中から、これからの薬剤師がどのように関わるべきかについて研究しています。

(4)医療データベースを用いた医薬品の安全性評価

医療現場では日々様々な薬物療法が行われており、医薬品の使用状況や有害事象の発現状況など種々雑多な情報が蓄積されています。そのような膨大な情報から、データマイニング手法を用いて、医薬品の安全性確保に有用な新たな情報を創出することを目指して研究を実施しています。これまで、臨床上重篤で特に注意を要する有害事象のリスクファクターの探索や、同効薬間での発現傾向の比較検討を通して医薬品の安全性評価に取り組んできました。また、小児、高齢者や各種臓器障害合併患者における有害事象、あるいは生命を脅かすまでには至らないものの患者さんのQOLの著しい低下を招くような有害事象に関しては、まだまだ情報が不足しています。そのような有害事象にも注目し、例えば小児における抗精神病薬の有害事象プロファイルについて新たな情報を発信してきました。今後は引き続き医薬品と有害事象との関連性、発現時期の把握やリスクファクターの探索といった観点でのデータ解析を行うとともに、得られた情報を活用できる形に加工して、実際に医療現場で医療者や患者さんに情報提供を行い、副作用の早期発見、早期対応につなげたいと考えています。

(5)薬物有害反応の軽減を目指した臨床薬理学研究

薬物には臨床開発時あるいは一般臨床での使用中に重篤な有害反応をきたし、開発中止や販売中止になるものがあります。このような薬物を早期に見出し、より高い安全性を確保することを目指したトキシコゲノミクス研究および臨床薬理学研究が大きな注目を集めています。このような背景のもと、より有効で安全な合理的薬物治療へのエビデンスを構築すべく基礎研究で見出した成果を臨床で展開しています。

(6)薬学臨床教育の改善・充実や教育効果の評価に関する研究

  1. 知識の統合から課題解決能力の向上につながるプロセスの理解を通じ、学習者の成長を促す効果的な教育手法を明らかにするとともに、教材・教育支援ツールの開発を通じた薬学教育への実装を目指します。
    薬学は生物・物理・化学を基盤に、様々な専門科目を通じて人・病・薬について深く学び、その知識を効果的に活用することを求められる学問です。薬学部の学生が、知識を統合していくプロセスやその影響因子について検討し、得られた知見に基づく効果的な教育手法を開発、実践していきたいと考えています。特に、薬学臨床領域の教育改善を目指して研究を展開していきます。
  2. 薬剤師による症例検討会や症例サマリの作成について、教育的側面から検討し、臨床や学生教育へのさらなる活用を目指します。
    薬剤師が臨床で研鑽を積み成長する過程において、自ら経験した症例を省察し、学びを深める過程は極めて重要だと考えます。症例検討会での発表や症例サマリの作成はそのよい機会になります。しかし、現状ではこのような取り組みが十分に行われていないと推測され、私たちはその普及が課題だと考えています。そこで、薬剤師による症例検討会や症例サマリの作成の実態を調査し課題を明らかにするとともに、教育ツールとしての可能性を検討します。

(7)医療機関と連携したクリニカルリサーチ

上記の研究テーマ以外にも、医療機関で発見された薬物療法の課題(医薬品の有効性や安全性に関する問題点、これまで経験したことがない有害事象など)や医療安全、医薬品管理などの医療マネジメント的側面の課題などから研究テーマを見出し、医療機関と協力しながら問題解決に向けて研究を進めます。

代表的論文

2021年

  1. Kazuki Matsui, Yutaro Mukai, Kota Sakakura, Kyoichi Wada, Tsutomu Nakamura, Atsufumi Kawabata, Nobue Terakawa, Naoki Hayakawa, Kengo Kusano, Kouichi Hosomi, Satoshi Yokoyama, Mitsutaka Takada: Relationship between serum bepridil concentration and corrected QT interval. Int J Clin Pharmacol Ther. 59(1):63-70, 2021
  2. Kanbayashi Y, Amaya F, Ueno H, Tabuchi Y, Ishikawa T, Takayama K, Taguchi T. Factors affecting the effect of naldemedine for opioid-induced constipation: a single-institution, retrospective analysis. Pharmazie. 2021;76:175-178. 
  3. Kanbayashi Y, Sakaguchi K, Hongo F, Ishikawa T, Tabuchi Y, Ukimura O, Takayama K, Taguchi T. Predictors for development of denosumab-induced hypocalcaemia in cancer patients with bone metastases determined by ordered logistic regression analysis. Sci Rep. 2021;11:978. 

2020年

  1. Hosohata K, Matsuoka H, Iwanaga K, Kumagai E: Urinary vanin-1 associated with chronic kidney disease in hypertensive patients: A pilot study. J Clin Hypertens (Greenwich), 22: 1458-1465, 2020.
  2. Hosohata K, Inada A, Oyama S, Doi T, Niinomi I, Wakabayashi T, Uchida M, Iwanaga K, Matsuoka H: Improvement of Blood Pressure Control by Adherence Check in Patients With Apparent Treatment-Resistant Hypertension: A Case Series. Clin Med Insights Case Rep, 13: 1-4, 2020
  3. Niinomi I, Hosohata K, Oyama S, Inada A, Wakabayashi T, Iwanaga K: Evaluation of adverse events associated with filgrastim originator and biosimilar using a spontaneous reporting system database. Pharmazie, 75: 151-153, 2020.
  4. Niinomi I, Hosohata K, Oyama S, Inada A, Hirai T, Iwanaga K: Drug-induced thrombotic microangiopathy using the Japanese pharmacovigilance database. Int J Clin Pharmacol Ther, 58: 543-549, 2020.
  5. Wakabayashi T, Hosohata K, Oyama S, Inada A, Ueno S, Kambara H, Iida T, Nakatsuji T, Uchida M, Iwanaga K: Comparison of Adverse Event Profiles of Tumor Necrosis Factor-Alfa Inhibitors: Analysis of a Spontaneous Reporting Database. Ther Clin Risk Manag, 16: 741-747, 2020.
  6. Kambara H, Hosohata K, Nakatsuji T, Ueno S, Oyama S, Inada A, Niinomi I, Wakabayashi T, Iwanaga K: Safety profile of vonoprazan compared with proton pump inhibitors: insight from a pharmacovigilance study. Pharmazie, 75: 527-530, 2020.
  7. Washino S, Hosohata K, Miyagawa T: Roles played by biomarkers of kidney injury in patients with upper urinary tract obstruction. Int J Mol Sci, 21: E5490, 2020.
  8. Kumagai E, Hosohata K, Furumachi K, Takai S: Range of plasma brain natriuretic peptide (BNP) levels in hemodialysis patients at high risk of 1-year mortality and their relationship with the nutritional status: A retrospective cohort study in one institute. Renal Replacement Therapy, 6: 32, 2020.
  9. Hirai T, Yamada R, Motoki K, Hosohata K, Itoh T: Geriatric patients are at a high risk of hypokalemia associated with Yokukansan preparation: a retrospective cohort study. Biol Pharm Bull, 43: 1742-1748, 2020.
  10. Mayako Uchida, Yuki Yamaguchi, Syuhei Hosomi, Hiroaki Ikesue, Nami Maegawa, Aoi Takano, Yuki Sato, Keiko Hosohata, Nobuyuki Muroi, Keisuke Tomii, Tohru Hashida, Tsutomu Nakamura: Risk factors for febrile neutropenia induced by docetaxel chemotherapy in patients with non-small cell lung cancer. Biol. Pharm. Bull. 43(8):1235-1240 (2020).
  11. Mayako Uchida, Yasuhiro Mori, Kenta Akiba, Moena Miyasaka, Tatsuya Hirano, Hiroaki Ikesue, Yuki Yamaguchi, Aoi Takano, Nami Maegawa, Yoshimitsu Shimomura, Keiko Hosohata, Nobuyuki Muroi, Takayuki Ishikawa, Tohru Hashida, Tsutomu Nakamura: Risk factors for skin toxicities associated with bendamustine-based chemotherapy in patients with non-Hodgkin lymphoma. Biol. Pharm. Bull. 43(10):1577-1582 (2020).
  12. Shigematsu N, Kawashiri T, Kobayashi D, Shimizu S, Mine K, Hiromoto S, Uchida M, Egashira N, Shimazoe T: Neuroprotective effect of alogliptin on oxaliplatin-induced peripheral neuropathy in vivo and in vitro. Scientific Reports. 10: 6734, 2020
  13. Takaya Uno, Kyoichi Wada, Kouichi Hosomi, Sachi Matsuda, Megumi Morii Ikura, Hiromi Takenaka, Nobue Terakawa, Akira Oita, Satoshi Yokoyama, Atsushi Kawase, Mitsutaka Takada: Drug interactions between tacrolimus and clotrimazole troche: a data mining approach followed by a pharmacokinetic study European Journal of Clinical Pharmacology 76(1) 117 - 125, 2020
  14. Kazuhiko Yamashita, Takashi Ogihara, Maho Hayashi, Takayuki Nakagawa, Yuma Ishizaki, Manabu Kume, Ikuko Yano, Riho Niigata, Jun Hiraoka, Hiroyuki Yasui, Tsutomu Nakamura: Association between dexamethasone treatment and alterations in serum concentrations of trace metals. Pharmazie. 75(5):218-222 (2020).
  15. Horii T, Konishi H, Kanbayashi Y: The Influence of Pre-Treatment with a Proton Pump Inhibitor / H2 Receptor Antagonists on Helicobacter Pylori Eradication Japanese Journal of gastroenterology and hepatology., V5(2): 1-2, 2020
  16. Kanbayashi Y, Amaya F, Ikoma K, Ueno H, Tabuchi Y, Ishikawa T, Takayama K, Taguchi T: Predictors of the usefulness of mirogabalin for neuropathic pain: a single-institution retrospective study. Pharmazie. 1;75(11):602-605, 2020.
  17. Kanbayashi Y, Ishikawa T, Tabuchi Y, Sakaguchi K, Ouchi Y, Otsuji E, Takayama K, Taguchi T: Predictive factors for the development of proteinuria in cancer patients treated with bevacizumab, ramucirumab, and aflibercept: a single-institution retrospective analysis. Sci Rep., 6;10(1):2011,2020.
  18. Kanbayashi Y, Sakaguchi K, Ishikawa T, Ouchi Y, Nakatsukasa K, Tabuchi Y, Kanehisa F, Hiramatsu M, Takagi R, Yokota I, Katoh N, Taguchi T: Comparison of the efficacy of cryotherapy and compression therapy for preventing nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: A prospective self-controlled trial. Breast., 49:219-224, 2020

2019年

  1. Yoshiaki Nagatani, Yoshinori Imamura, Tsutomu Nakamura, Kazuhiko Yamashita, Mamoru Okuno, Hiroyuki Yasui, Jun Hiraoka, Riho Niigata, Keiji Kono, Yasuko Hyogo, Hirotaka Suto, Kei Takenaka, Yohei Funakoshi, Masanori Toyoda, Naomi Kiyota, Hironobu Minami: Pharmacokinetics of oxaliplatin in a hemodialysis patient with metastatic colon cancer, Int J Oncol Res. 2(2):017(2019).
  2. Hosohata K, Jin D, Takai S, Iwanaga K: Involvement of vanin-1 in ameliorating of oxidative renal injury in Dahl-salt sensitive rats, Int J Mol Sci. 20: E4481(2019)
  3. Niinomi I, Hosohata K, Mori Y, Yamaguchi Y, Wakabayashi T, Uchida M, Iwanaga K: Evaluation of adverse events focusing on infection associated with infliximab originator and biosimilar using a spontaneous reporting system database, Journal of Pharmaceutical Health Care and Sciences. 5: 21(2019)
  4. Niinomi I, Hosohata K, Oyama S, Inada A, Wakabayashi T, Iwanaga K: Pharmacovigilance assessment of drug-induced acute pancreatitis using a spontaneous reporting database, Int J Toxicol. 38: 487-492(2019)
  5. Hosohata K, Mise N, Kayama F, Iwanaga K: Augmentation of cadmium-induced oxidative cytotoxicity by pioglitazone in renal tubular epithelial cells, Toxicol Ind Health. 35: 530-536(2019)
  6. Inada A, Oyama S, Niinomi I, Wakabayashi T, Iwanaga K, Hosohata K: Association of Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs in pediatric patients: Subgroup analysis based on a Japanese spontaneous database, J Clin Pharm Ther. 44: 775-779(2019)
  7. Hosohata K, Oyama S, Niinomi I, Wakabayashi T, Inada A, Iwanaga K: Comparison of safety profiles of new oral anticoagulants with warfarin using the Japanese spontaneous reporting database, Clin Drug Investig. 39: 665-670(2019)
  8. Washino S, Hosohata K, Oshima M, Okochi T, Konishi T, Nakamura Y, Saito K, Miyagawa T: A novel biomarker for acute kidney injury, vanin-1, for obstructive nephropathy: A prospective cohort pilot study, Int J Mol Sci. 20: E899(2019)
  9. Hosohata K, Inada A, Oyama S, Niinomi I, Wakabayashi T, Iwanaga K: Adverse cutaneous drug reactions associated with old- and new-generation antiepileptic drugs using the Japanese pharmacovigilance database, Clin Drug Investig. 39: 363-368(2019)
  10. Inada A, Hosohata K, Oyama S, Niinomi I, Mori Y, Yamaguchi Y, Uchida M, Iwanaga K: Evaluation of medication-related osteonecrosis of the jaw using the Japanese Adverse Drug Event Report Database, Therapeutics and Clinical Risk Management. 15: 59-64(2019)
  11. Hosohata K, Inada A, Oyama S, Furushima D, Yamada H, Iwanaga K: Surveillance of drugs that most frequently induce acute kidney injury: A pharmacovigilance approach, J Clin Pharm Ther. 44: 49-53(2019)
  12. Uchida M, Nakamura T, Shima T, Mori Y, Yoshimoto G, Kato K, Shimokawa M, Hosohata K, Miyamoto T, Akashi K: Evaluation of the compliance with antiemetic guidelines for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancy, Pharmazie. 74 : 250-254(2019)
  13. Uchida M, Kondo Y, Suzuki S, Hosohata K: Evaluation of acute kidney injury associated with anti-cancer drugs used in gastric cancer in the Japanese Adverse Drug Event Report database, Annals of Pharmacotherapy. 53 : 1200-1206(2019)
  14. Uchida M, Suzuki S, Sugawara S, Suga Y, Kokubun H, Uesawa Y, Nakagawa T, Takase H: A nationwide survey of hospital pharmacist interventions to improve polypharmacy for patients with cancer in palliative care in Japan, J Pharm Health Care Sci. 5 : 14, eCollection(2019)
  15. Uchida M, Nakamura T, Watanabe H, Kato K, Miyamoto T, Akashi K, Masuda S: Usefulness of medication instruction sheets for sharing information on cancer chemotherapy within the health care team, Pharmazie. 74 : 566-569(2019)
  16. Uchida M, Hada M, Yamada M, Inma D, Ariyoshi S, Aoki K, Inoue S, Shimazoe T, Mitsuiki K, Haraguchi T: Impact of a systematic education model for palliative care in cancer, Pharmazie. 74 : 499-504(2019)
  17. Suzuki S, Uchida M, Sugawara S, Suga Y, Kokubun H, Uesawa Y, Nakagawa T, Takase H: A nationwide survey of community pharmacist interventions on polypharmacy in opioid use and non-use cancer patients in Japan, Biol Pharm Bull. 42 : 1164-1171(2019)
  18. Sugawara H, Uchida M, Suzuki S, Suga Y, Uesawa U, Nakagawa T, Takase H: Analyses of respiratory depression associated with opioids in cancer patients based on the Japanese Adverse Drug Event Report Database, Biol Pharm Bull. 42 : 1185-1191(2019)
  19. Suga Y, Uchida M, Suzuki S, Sugawara H, Torigoe K, Futamura A, Uesawa Y, Nakagawa T, Takase H: Current status of adverse events related with opioid analgesics in Japan: Assessment based on Japanese Adverse Drug Event Report database, Biol Pharm Bull. 42 : 801-806(2019)
  20. 渡邊裕之, 内田まやこ, 増田智先: がん薬物療法の適正化推進に向けた臨床薬学的研究, YAKUGAKU ZASSHI, 139:901-909(2019)
  21. Komasawa N, Ohashi T, Take A, Doi Y, Kadoyama K, Terasaki F, Dote T, Akazawa C: Hybrid simulation training utilizing augmented reality and simulator for interprofessional advanced life support training, J Clin Anesth. 57:106-107(2019)
  22. Kanbayashi Y, Sakaguchi K, Nakatsukasa K, Ouchi Y, Tabuchi Y, Yoshioka T, Ishikawa T, Takayama K, Taguchi T: Predictive factors for taxane acute pain syndrome determined by ordered logistic regression analysis, Support Care Cancer. 27:2673-2677(2019)
  23. Takaya Uno, Kyoichi Wada, Sachi Matsuda, Megumi Ikura, Hiromi Takenaka, Nobue Terakawa, Akira Oita, Satoshi Yokoyama, Atsushi Kawase, Kouichi Hosomi, Mitsutaka Takada: Clotrimazole troches can alter everolimus pharmacokinetics in post-transplant patients: A case report, British Journal of Clinical Pharmacology. 85, 2176-2178(2019)

2018年

  1. Yamato M, Wada K, Hayashi T, Fujimoto M, Hosomi K, Oita A, Takada M: Association between serum amiodarone and N-desethylamiodarone concentrations and development of thyroid dysfunction, Clinical Drug Investigation. 38: 39-48(2018).
  2. Nakagita K, Wada K, Terada Y, Matsuda S, Terakawa N, Oita A, Takada M., The effect of fluconazole on the pharmacokinetics of everolimus and tacrolimus in a heart transplant recipient: A case report . Int J Clin Pharmacol Ther. 56: 270-276(2018).
  3. Nakagita K, Wada K, Mukai Y, Uno T, Nishino R, Matsuda S, Takenaka H, Terakawa N, Oita A, Takada M, Effects of vitamin K epoxide reductase complex 1 gene polymorphisms on warfarin control in Japanese patients with left ventricular assist devices (LVAD), Eur J Clin Pharmacol. 74: 885-894(2018).
  4. Uno T, Wada K, Matsuda S, Terada Y, Oita A, Kawase A, Takada M, Impact of the CYP3A5*1 Allele on the Pharmacokinetics of Tacrolimus in Japanese Heart Transplant Patients, Eur J Drug Metab Pharmacokinet. 43:665-673(2018)
  5. Wakamiya A, Seguchi O, Shionoiri A, Kumai Y, Kuroda K, Nakajima S, Yanase M, Matsuda S, Wada K, Matsumoto Y, Fukushima S, Fujita T, Kobayashi J, Fukushima N, Paradoxical Reaction of Tuberculosis in a Heart Transplant Recipient During Antituberculosis Therapy: A Case Report, Transplant Proc. 50: 947-949(2018).
  6. Seguchi O, Kuroda K, Kumai Y, Nakajima S, Yanase M, Wada K, Matsumoto Y, Fukushima S, Fujita T, Kobayashi J, Fukushima N. Clinical Outcomes of Patients With the HeartMate II Left Ventricular Assist Device: A Single-center Experience From Japan. Transplant Proc. 50: 2726-2732(2018).
  7. Kimura Y, Seguchi O, Iwasaki K, Toda K, Kikuchi N, Matsuda S, Kumai Y, Kuroda K, Wada K, Matsumoto Y, Fukushima S, Yanase M, Fujita T, Kobayashi J, Fukushima N. Impact of Coronary Artery Calcification in the Donor Heart on Transmitted Coronary Artery Disease in Heart Transplant Recipients. Circ J. 82: 3021-3028(2018).
  8. Kanbayashi Y, Sakaguchi K, Nakatsukasa K, Ouchi Y, Tabuchi Y, Yoshioka T, Ishikawa T, Takayama K, Taguchi T. Predictive factors for taxane acute pain syndrome determined by ordered logistic regression analysis. Support Care Cancer. (2018).
  9. Kanbayashi Y, Ishikawa T, Kanazawa M, Nakajima Y, Tabuchi Y, Kawano R, Yoshioka T, Yoshida N, Hosokawa T, Takayama K, Taguchi T. Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis. Med Oncol. 35:82 (2018).
  10. Kanbayashi Y, Ishikawa T, Kanazawa M, Nakajima Y, Kawano R, Tabuchi Y, Yoshioka T, Ihara N, Hosokawa T, Takayama K, Shikata K, Taguchi T. Predictive factors in patients eligible for pegfilgrastim prophylaxis focusing on RDI using ordered logistic regression analysis. Med Oncol. 35:55 (2018).
  11. Hosohata K, Jin Denan, Shinji Takai, Iwanaga K. Vanin-1 in the renal pelvic urine reflects kidney injury in a rat model of hydronephrosis. Int J Mol Sci, 19: E3186, 2018.
  12. Hosohata K. Can focal segmental glomerulosclerosis be differentiated from minimal change nephrotic syndrome using biomarkers? Am J Med Sci, 355: 305-306, 2018.
  13. Hosohata K, Matsuoka E, Inada A, Oyama S, Niinomi I, Mori Y, Yamaguchi Y, Uchida M, Iwanaga K. Differential profiles of adverse events associated with mycophenolate mofetil between adult and pediatric renal transplant patients. J Int Med Res, 46: 4617-4623, 2018.
  14. Oyama S, Hosohata K, Inada A, Niinomi I, Mori Y, Yamaguchi Y, Uchida M, Iwanaga K. Drug-induced tubulointerstitial nephritis in a retrospective study using spontaneous reporting system database. Ther Clin Risk Manag, 14: 1599-1604, 2018.
  15. Washino S, Hosohata K, Jin D, Takai S, Miyagawa T. Early urinary biomarkers of renal tubular damages by a high-salt intake independent of blood pressure in normotensive rats. Clin Exp Pharmacol Physiol, 45: 261-268, 2018.
  16. Uchida M, Nakamura T, Makihara Y, Suetsugu K, Ikesue H, Mori Y, Kato K, Shiratsuchi M, Hosohata K, Miyamoto T, Akashi K. Comparison of antiemetic effects of granisetron and palonosetron in patients receiving bendamustine-based chemotherapy. Pharmazie. 73: 304-308, 2018
  17. Uchida M, Nakamura T, Hata K, Watanabe H, Mori Y, Kato K, Kamezaki K, Takenaka K, Shiratsuchi M, Hosohata K, Miyamoto T, Akashi K. Antiemetic efficacy and safety of granisetron or palonosetron alone and in combination with a corticosteroid for ABVD therapy-induced nausea and vomiting. J Pharm Health Care Sci. eCollection 2018
  18. Uchida M, Nakamura T, Shima T, Mori Y, Yoshimoto G, Kato K, Shimokawa M, Hosohata K, Miyamoto T, Akashi K. Evaluation of compliance with antiemetic guidelines for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancy. Pharmazie. in press.
  19. Negoro T, Yano R, Yoshimura M, Suehiro Y, Yamashita S, Kodawara T, Watanabe K, Tsukamoto H, Nakamura T, Kadowaki M, Morikawa M, Umeda Y, Anzai M, Ishizuka T, Goto N. Influence of UGT1A1 polymorphism on etoposide plus platinum-induced Influence of UGT1A1 polymorphism on etoposide plus platinum-induced neutropenia in Japanese patients with small-cell lung cancer. Int J Clin Oncol. 2018
  20. Komasawa N, Ohashi T, Take A, Doi Y, Kadoyama K, Dote T, Akazawa C. Interprofessional simulation for rapid response system should be developed with step by step process to multiple learning purposes. Am J Emerg Med. 2018

2017年

  1. Uchida M, Mori Y, Nakamura T, Kato K, Kamezaki K, Takenaka K, Shiratsuchi M, Kadoyama K, Miyamoto T, Akashi K. Comparison between Antiemetic Effects of Palonosetron and Granisetron on Chemotherapy-Induced Nausea and Vomiting in Japanese Patients Treated with R-CHOP. Biol Pharm Bull. 40(9):1499-1505(2017)
  2. Hosohata K. Biomarkers for Chronic Kidney Disease associated with a high salt intake. Int J Mol Sci. 18: E2080, 2017.
  3. Suetsugu K, Ikesue H, Miyamoto T, Shiratsuchi M, Yamamoto-Taguchi N, Tsuchiya Y, Matsukawa K, Uchida M, Watanabe H, Akashi K, Masuda S. Analysis of the variable factors influencing tacrolimus blood concentration during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation. Int J Hematol., 105(3):361-368 (2017)


2016年

  1. T. Nakamura, M. Takahashi, R. Niigata, K. Yamashita, M. Kume, M. Hirai, H. Yasui.Changes in blood concentrations of trace metals in cancer patients receiving cisplatin-based chemotherapy. Biomed Rep., in press.

  2. S. Kawauchi, T. Nakamura, S. Horibe, T. Tanahashi, S. Mizuno, T. Hamaguchi, Y. Rikitake. Mechanism of changes in hepatic CYP3A expression in a rat model of indomethacin-induced small intestinal ulcers. Biopharm Drug Disposit., in press.

  3. S. Koubuchi, M. Aoki, C. Inoue, H. Murakami, A. Kuwahara, T. Nakamura, H. Yasui, Y. Ito, K. Takada, T. Sakaeda. Transport of azithromycin into extravascular space in rats. Antimicrob Agents Chemother., in press.

  4. M. Miura, A. Kuwahara, A. Tomozawa, N. Omae, M. Yamamori, K. Kadoyama, T. Sakaeda. Lower Body Mass Index is a Risk Factor for In-Hospital Mortality of Elderly Japanese Patients Treated with Ampicillin/sulbactam. Int J Med Sci., 13, 749-753 (2016)

  5. Suetsugu K, Ikesue H, Miyamoto T, Shiratsuchi M, Yamamoto-Taguchi N, Tsuchiya Y, Matsukawa K, Uchida M, Watanabe H, Akashi K, Masuda S. Analysis of the variable factors influencing tacrolimus blood concentration during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation. Int J Hematol. in press.

  6. K. Hosohata. Role of Oxidative Stress in Drug-Induced Kidney Injury. Int J Mol Sci. 17(11), E1826, 2016.

  7. K. Hosohata, S. Washino, T. Kubo, A. Fujisaki, S. Kurokawa, H. Ando, A. Fujimura, T. Morita. Early prediction of cisplatin-induced nephrotoxicity by urinary vanin-1 in patients with urothelial carcinoma. Toxicology, 359-360, 71-75 (2016).


2015年

  1. K. Iwanaga, Y. Higashiyama, M. Miyazaki, M. Kakemi. Enhancing mechanism of intestinal absorption of highly lipophilic compounds using microemulsion –Quantitative analysis of the partitioning to the mesenteric lymph in intestinal cells–. Asian Journal of Pharmaceutical Sciences, 10, 186–193 (2015).

  2. M. Miyazaki, T. Kawase, C. Nishimura, T. Kitamura, K. Iwanaga and M. Kakemi. Pharmacokinetics and toxicity of repeated oral etoposide is altered by morphine coadministration in rats. Eur J Drug Metab Pharmacokinet, 40, 335–341 (2015).

  3. G. Kimura, K. Kadoyama, J.B. Brown, T. Nakamura, I. Miki, K. Nishiguchi, T. Sakaeda, Y. Okuno. Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database. Int J Med Sci. 12(2), 135-140 (2015).


2014年

  1. K. Iwanaga, Y. Kawabata, M. Miyazaki, M. Kakemi. Quantitative analysis of the effect of triglyceride alkyl-chain length on the partitioning of highly lipophilic compounds to the mesenteric lymph in intestinal cells. Arch Pharm Res., 37, 937–946. (2014).

  2. M. Miyazaki, C. Nishimura, M. Minamida, K. Iwanaga, M. Kakemi. Pharmacokinetic assessment of Absorptive Interaction of Oral Etoposide and Morphine in Rats. Biol Pharm Bull., 37 (3), 371–377 (2014).

  3. S. Kawauchi, T. Nakamura, H. Yasui, C. Nishikawa, I. Miki, J. Inoue, S. Horibe, T. Hamaguchi, T. Tanahashi, S. Mizuno. Intestinal and hepatic expression of cytochrome P450s and mdr1a in rats with indomethacin-induced small intestinal ulcers. Int J Med Sci. 11(12), 1208-1217 (2014).

  4. S. Kawauchi, T. Nakamura, I. Miki, J. Inoue, T. Hamaguchi, T. Tanahashi, S. Mizuno. Down-regulation of CYP3A and P-glycoprotein in the secondary inflammatory response of mice with dextran sulfate sodium-induced colitis and its contribution to cyclosporine A blood concentrations. J Pharmacol Sci., 124(2), 180-191 (2014).

  5. T. Minegaki, A. Kuwahara, M. Yamamori, T. Nakamura, T. Okuno, I. Miki, H. Omatsu, T. Tamura, M. Hirai, T. Azuma, T. Sakaeda, K. Nishiguchi. Genetic polymorphisms in SLC23A2 as predictive biomarkers of severe acute toxicities after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Int J Med Sci., 11(4), 321-326 (2014).

  6. H. Tsukamoto, T. Higashi, T. Nakamura, R. Yano, Y. Hida, Y. Muroi, S. Ikegaya, H. Iwasaki, M. Masada. Clinical effect of a multidisciplinary team approach to the initial treatment of patients with hospital-acquired bloodstream infections at a Japanese university hospital. Am J Infect Control., 42, 970-975 (2014)

  7. T. Kodawara, S. Masuda, Y. Yano, K. Matsubara, T. Nakamura, M. Masada. Inhibitory effect of ciprofloxacin on β-glucuronidase-mediated deconjugation of mycophenolic acid glucuronide. Biopharm Drug Disp., 35, 275-283 (2014)

  8. K. Watanabe, N. Goto, T. Nakamura, M. Masada. Inhibitory effect of ciprofloxacin on β-glucuronidase-mediated deconjugation of mycophenolic acid glucuronide. Biol. Pharm. Bull., 36, 719-722 (2014)

  9. T. Sakaeda, K. Kadoyama, K. Minami, Y. Okuno. Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms. Int J Med Sci., 11, 461-465 (2014)

  10. Ikesue H, Tsuji T, Hata K, Watanabe H, Mishima K, Uchida M, Egashira N, Miyamoto T, Baba E, Akashi K, Takayama K, Nakanishi Y, Tokunaga E, Okamoto T, Maehara Y, Yokomizo A, Naito S, Kubo M, Tanaka M. Time course of calcium concentrations and risk factors for hypocalcemia in patients receiving denosumab for the treatment of bone metastases from cancer. Ann Pharmacother., 48, 1159-1165 (2014)

  11. Kumagai H, Kusaba H, Okumura Y, Komoda M, Nakano M, Tamura S, Uchida M, Nagata K, Arita S, Ariyama H, Takaishi S, Akashi K, Baba E. Efficacy and safety of an increased-dose of dexamethasone in patients receiving fosaprepitant chemotherapy in Japan. Asian Pac J Cancer Prev., 15, 459-463 (2014)


2013年

  1. C. Yamawaki, M. Takahashi, K. Takara, M. Kume, M. Hirai, H. Yasui, T. Nakamura. Effect of dexamethasone on extracellular secretion of cystatin C in cancer cell lines. Biomed Rep., 1, 111-114 (2013).

  2. H. Omatsu, A. Kuwahara, M. Yamamori, M. Fujita, T. Okuno, I. Miki, T. Tamura, K. Nishiguchi, N. Okamura, T. Nakamura, T. Azuma, T. Hirano, K. Ozawa, M. Hirai. TNF-α -857C>T genotype is predictive of clinical response after treatment with definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Int J Med Sci., 10(12), 1755-1760 (2013).

  3. N. Kaneko, A. Gotoh, N. Okamura, E. Matsuo, S. Terao, M. Watanabe, T. Nakamura, M. Ikekita, K. Okumura, O. Nishimura. Potential tumor markers of renal cell carcinoma: α-enolase for postoperative follow-up and galectin-1 and galectin-3 for primary detection. Int J Urol., 20(5), 530-535 (2013).

  4. T. Yagami, Y. Yamamoto, H. Kohma, T. Nakamura, N. Takasu, N. Okamura. L-type voltage-dependent calcium channel is involved in the snake venom group IA secretory phospholipase A2-induced neuronal apoptosis. Neurotoxicology, 35, 146-153 (2013)

  5. K. Iwanaga, T. Honjo, M. Miyazaki, M, Kakemi Time-dependent changes in hepatic and intestinal induction of cytochrome P450 3A after administration of dexamethasone to rats. Xenobiotica, 43, 765–773 (2013).

  6. K. Iwanaga, S. Kato, M. Miyazaki, M. Kakemi. Enhancing the intestinal absorption of poorly water-soluble weak-acidic compound by controlling local pH. Drug. Dev. Ind. Pharm., 39, 1887–1894 (2013).

  7. H. Ohnaka, H. Tsukamoto, T. Nakamura, R. Yano, K. Watanabe, T. Igarashi, N. Goto, M. Masada. Predictors of response of patients with solid tumors to granulocyte colony-stimulating factor. Int J Clin Pharm, 35, 45-50 (2013)

  8. H. Murakami, T. Sakaeda, K. Kadoyama, Y. Okuno. Gender Effects on Statin-Associated Muscular Adverse Events: An Analysis of the FDA AERS Database. Pharmacology & Pharmacy, 4, 340-346 (2013)

  9. K. Yoshimura, K. Kadoyama, T. Sakaeda, Y. Sugino, O. Ogawa, Y. Okuno. A Survey of the FAERS database concerning the adverse event profiles of α1-adrenoreceptor blockers for lower urinary tract symptoms. Int J Med Sci., 10, 864-869 (2013)

  10. T. Sakaeda, A. Tamon, K. Kadoyama, Y. Okuno. Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci., 10, 796-803 (2013)

  11. Uchida M, Kato K, Ikesue H, Ichinose K, Hiraiwa H, Sakurai A, Muta T, Takenaka K, Iwasaki H, Miyamoto T, Teshima T, Shiratsuchi M, Suetsugu K, Nagata K, Egashira N, Akashi K, Oishi R. Efficacy and safety of aprepitant in allogeneic hematopoietic stem cell transplantation. Pharmacotherapy., 33, 893-901 (2013)

  12. Uchida M, Ikesue H, Miyamoto T, Kato K, Suetsugu K, Ichinose K, Hiraiwa H, Sakurai A, Takenaka K, Muta T, Iwasaki H, Teshima T, Shiratsuchi M, Egashira N, Akashi K, Oishi R. Effectiveness and safety of antiemetic aprepitant in Japanese patients receiving high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation. Biol Pharm Bull., 36, 819-824 (2013)

  13. Uchida M, Ikesue H, Kato K, Ichinose K, Hiraiwa H, Sakurai A, Takenaka K, Iwasaki H, Miyamoto T, Teshima T, Egashira N, Akashi K, Oishi R. Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy. Am J Health Syst Pharm., 70, 343-349 (2013)

  14. Watanabe H, Ikesue H, Tsujikawa T, Nagata K, Uchida M, Suetsugu K, Egashira N, Muta T, Kato K, Takenaka K, Ohga S, Matsushima T, Shiratsuchi M, Miyamoto T, Teshima T, Akashi K, Oishi R. Decrease in venous irritation by adjusting the concentration of injected bendamustine. Biol Pharm Bull., 36, 574-578 (2013)


2012年

  1. T. Tamura, A. Kuwahara, M. Yamamori, K. Nishiguchi, T. Nakamura, T. Okuno, I. Miki, Y. Manabe, T. Sakaeda. VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Int J Med Sci., 9(10), 833-837 (2012).

  2. I. Miki, T. Nakamura, A. Kuwahara, M. Yamamori, K. Nishiguchi, T. Tamura, T. Okuno, H. Omatsu, S. Mizuno, M. Hirai, T. Azuma, T. Sakaeda. THRB genetic polymorphisms can predict severe myelotoxicity after definitive chemoradiotherapy in patients with esophageal squamous cell carcinoma. Int J Med Sci., 9(9), 748-756 (2012).

  3. M. Fujita, C. Tohji, Y. Honda, Y. Yamamoto, T. Nakamura, T. Yagami, M. Yamamori, N. Okamura. Cytotoxicity of 15-deoxy-Δ12,14-prostaglandin J2 through PPARγ-independent pathway and the involvement of the JNK and Akt pathway in renal cell carcinoma. Int J Med Sci., 9(7), 555-566 (2012).

  4. M. Kume, H. Yasui, Y. Yoshikawa, M. Horinouchi, K. Higashiguchi, Y. Kobayashi, D. Kuroda, T. Hirano, M. Hirai, T. Nakamura. Transient elevation of serum cystatin C concentrations during perioperative cisplatin-based chemotherapy in esophageal cancer patients. Cancer Chemother Pharmacol., 69(6), 1537-1544 (2012).

  5. M. Fujita, M. Tohi, K. Sawada, Y. Yamamoto, T. Nakamura, T. Yagami, M. Yamamori, N. Okamura. Involvement of the mevalonate pathway in the antiproliferative effect of zoledronate on ACHN renal cell carcinoma cells. Oncol Rep., 27(5), 1371-1376 (2012).

  6. Z. Adhim, X. Lin, W. Huang, N. Morishita, T. Nakamura, H. Yasui, N. Otsuki, K. Shigemura, M. Fujisawa, K. Nibu, T. Shirakawa. E10A, an adenovirus carrying endostatin gene, dramatically increased the tumor drug concentration of metronomic chemotherapy with low-dose cisplatin in axenograft mouse model for head and neck squamous cell carcinoma. Cancer Gene Ther., 19(2), 144-152 (2012).

  7. K. Iwanaga, K. Arimune, M. Miyazaki, M. Shibano, M. Taniguchi, K. Baba, M. Kakemi. Effects of Furanocoumarins in Kampo Extract Medicines on Rat Intestinal Absorption of CYP3A and P-glycoprotein Substrate Drugs in Vivo. Arch Pharm Res., 35, 1055-1064 (2012).

  8. R. Shimizu, M. Miyazaki, K. Iwanaga, M. Kakemi. The pharmacokinetic-pharmacodynamic assessment of the hypotensive effect after coadministration of losartan and hydrochlorothiazide in spontaneously hypertensive rats. Drug Metab Pharmacokin., 27, 207-215 (2012).

  9. K. Iwanaga, M. Kawai, M. Miyazaki, M. Kakemi. Application of organogels as oral controlled release formulations of hydrophilic drugs. Int J Pharm., 436, 869-872 (2012).

  10. 釘山 直子,岩永 一範,宮崎 誠,掛見 正郎 抗リウマチ薬の関節内投与のための最適製剤設計に関する基本的検討  Bulletin of Osaka University of Pharmaceutical Sciences, 6, 51-60 (2012).

  11. K. Kadoyama, T. Sakaeda, A. Tamon, Y. Okuno. Adverse event profile of tigecycline:data mining of the public version of the U.S. Food and Drug Administration Adverse Event Reporting System. Biol Pharm Bull., 35, 967-970 (2012)

  12. T. Tamura, T. Sakaeda, K. Kadoyama, Y. Okuno. Aspirin- and clopidogrel - associated bleeding complications: data mining of the public version of the FDA Adverse Event Reporting System, AERS. Int J Med Sci., 9, 441-446 (2012)

  13. T. Tamura, T. Sakaeda, K. Kadoyama, Y. Okuno. Omeprazole- and esomeprazole - associated hypomagnesaemia: data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci., 9, 322-326 (2012)

  14. K. Kadoyama, I. Miki, T Tamura, JB Brown, T Sakaeda, Y. Okuno. Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations. Int J Med Sci., 9, 33-39 (2012)